<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974775</url>
  </required_header>
  <id_info>
    <org_study_id>SWECRIT</org_study_id>
    <nct_id>NCT04974775</nct_id>
  </id_info>
  <brief_title>Swecrit Biobank - Blood Samples From Critically Ill Patients and Healthy Controls</brief_title>
  <acronym>SWECRIT</acronym>
  <official_title>Swecrit Biobank - Blood Samples From Critically Ill Patients and Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Skane University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blood samples are collected and stored in a biobank for later analysis of circulating&#xD;
      substances in peripheral blood and genetic variations in patients with severe critical&#xD;
      illness and risk of death. The aim is to analyze stored samples in order to identify&#xD;
      substances that can help predict the outcome of critically ill patients, but also to optimize&#xD;
      treatment and possibly prevent serious illness and death in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SWECRIT is a regional, multicenter study with prospective collection of blood samples and&#xD;
      background information from critically ill patients, admitted to an Intensive Care Unit (ICU)&#xD;
      in Region Skåne, Sweden. Patients were originally categorized into four study cohorts a)&#xD;
      cardiac arrest, b) sepsis, c) influenza, and d) trauma. In April of 2020, a fifth study&#xD;
      cohort, covid19, was added to the original ones. In addition, a control group of healthy&#xD;
      controls has been enrolled.&#xD;
&#xD;
      Diagnoses, disease course, treatment results and survival are prospectively collected from&#xD;
      all critically ill patients in the Patient Administrative System for Intensive Care Units&#xD;
      (PASIVA). PASIVA is the portal by which collected laboratory and physiological data are&#xD;
      entered into the Swedish Intensive Care Register (SIR). Further data are collected&#xD;
      retrospectively from other health-related registers, such as the Swedish Population Register,&#xD;
      the International Cardiac Arrest Registry (INTCAR), The Swedish CPR Registry, the Swedish&#xD;
      Trauma Registry (SweTrau), and the Regional quality register Covid-IR (covid19 disease).&#xD;
&#xD;
      Specifically for the covid19-cohort, detailed face-to-face follow-up will be performed of all&#xD;
      survivors at 3 &amp; 12 months and a telephone interview after 3 years. Questionnaires (see&#xD;
      below) will be sent to patients prior to the follow-up. Questions about well-being in&#xD;
      general, quality-of-life, sleeping disorders, psychological and psychiatric problems will be&#xD;
      addressed.&#xD;
&#xD;
      Collected blood samples in the ICU are processed by clinical chemistry at each participating&#xD;
      hospital and frozen specimens of whole blood, serum, and plasma (200 ul aliquots) are sent to&#xD;
      the biobank BD-47 in Region Skane for long-term storage (maximum 20 years).&#xD;
&#xD;
      The circulating substances and genetic markers, i.e. biomarkers that will be analyzed are:&#xD;
      proteins (markers of inflammation, stress, infection, neurologic injury, myocardial injury&#xD;
      and endothelial function) and other circulating substances in the blood (metabolomics), genes&#xD;
      (DNA) from the entire genome, epigenetic changes (eg methylation status of DNA), gene&#xD;
      fragments (eg secretory DNA), various forms of RNA such as micro-RNA &amp; longcoding RNA.&#xD;
&#xD;
      Research questions for future analyzes of collected samples are specified but subject to&#xD;
      change, depending on progress and development in the specific research field of each study&#xD;
      cohort.&#xD;
&#xD;
        1. Identification and use of biomarkers for assessment of severity of disease and&#xD;
           trajectory over time in the ICU will be the main area of research.&#xD;
&#xD;
        2. Assessment of neurological prognosis and outcomes will be a common denominator in&#xD;
           several studies.&#xD;
&#xD;
        3. Descriptive statistics and regression analyses will be performed in order to identify&#xD;
           independent variables (biomarkers) of importance for prognosis and outcomes.&#xD;
&#xD;
      Inquiries to access the sample collection for research purpose can be sent to the central&#xD;
      contacts listed below.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality (all)</measure>
    <time_frame>6 months</time_frame>
    <description>Primary outcome when functional outcome cannot be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with good neurological outcome 1 (all)</measure>
    <time_frame>3-6 months</time_frame>
    <description>Neurological outcome assessed using Cerebral Performance Category 1-5 (CPC 1-5), CPC 1 representing the best and CPC 5 the worst outcome. Good outcome is defined as CPC 1-2, poor outcome as CPC 3-5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with good neurological outcome 2 (all)</measure>
    <time_frame>3-6 months</time_frame>
    <description>Modified Rankin Score 0-6 (mRS 0-6), mRS 0 representing the best and mRS 6 representing the worst outcome. Good outcome is defined as mRS 0-3, poor outcome as mRS 3-6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological outcome 3 (covid19)</measure>
    <time_frame>3-6 months</time_frame>
    <description>Glasgow Outcome Scale Extended 1-8 (GOSE 1-8), GOSE 1 representing the worst outcome and GOSE 8 the best outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Severity of the Acute Respiratory Distress Syndrome (ARDS) (covid19)</measure>
    <time_frame>On ICU admission</time_frame>
    <description>Patients fulfilling the ARDS criteria are categorized into mild, moderate or severe, depending on the ratio of arterial oxygen partial pressure (mmHg) to fractional inspired oxygen (FiO2). Mild: &lt; 300, Moderate: &lt; 200, Severe: &lt; 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with pathological Pulmonary Function Testing (PFT)</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>A composite of Total Lung Capacity (TLC) &amp; Diffusion capacity (DLCO) compared to a population norm. Less than 80 % of the (age-adjusted) population norm is considered pathological.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective respiratory function (covid19)</measure>
    <time_frame>3, 12 and 36 months</time_frame>
    <description>Saint George's Respiratory Questionnaire 0-100 (SGRQ 0-100), lower values representing better function and higher values representing worse function. 8.41 (SD 11.33) is considered a normative value (Spanish population).</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical problems (covid19)</measure>
    <time_frame>3, 12 and 36 months</time_frame>
    <description>Short form Health Survey, version 2, physical function 10 (SF-36 v.2 PF-10), 10 items, higher score for each item represents better function. Scores are transformed to T-scores based on norm-based values. A T-score of 50 indicates the norm mean for each item. At a group level scores &lt;47 and individual scores &lt;45 indicate low physical function.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with significant Fatigue (covid19)</measure>
    <time_frame>3, 12 and 36 months</time_frame>
    <description>Modified fatigue impact scale 0-84 (MFIS 0-84), higher values representing more fatigue and lower numbers representing less fatigue. A value &gt;38 discriminates significant fatigue.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital Anxiety and Depression Scale (covid19)</measure>
    <time_frame>3, 12 and 36 months</time_frame>
    <description>Anxiety and depression. Two sub-scales with 7 items in each, higher values represent more anxiety and depression, &gt;8 points in each sub-scale indicates significant symptoms of anxiety and depression.</description>
  </other_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">8500</enrollment>
  <condition>Critical Illness</condition>
  <condition>Cardiac Arrest</condition>
  <condition>Sepsis</condition>
  <condition>Influenza</condition>
  <condition>Covid19</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>Critically Ill</arm_group_label>
    <description>Critically ill patients and patients in need of post-operative intensive care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiac Arrest</arm_group_label>
    <description>Cardiac Arrest according to the ICD-10 I469 diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sepsis</arm_group_label>
    <description>Sepsis according to the sepsis-3 criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Covid-19</arm_group_label>
    <description>Critically ill patients with a positive Covid-19 test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza</arm_group_label>
    <description>Critically ill patients with a positive influenza test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trauma</arm_group_label>
    <description>Critically ill patients after a severe traumatic event.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy at the time of blood sampling</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Sampling on admission to ICU (all patients)</description>
    <arm_group_label>Cardiac Arrest</arm_group_label>
    <arm_group_label>Covid-19</arm_group_label>
    <arm_group_label>Critically Ill</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Influenza</arm_group_label>
    <arm_group_label>Sepsis</arm_group_label>
    <arm_group_label>Trauma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood collection, serial sampling</intervention_name>
    <description>Additional sampling to admission samples in&#xD;
the Cardiac Arrest group after 12 and 48 hours&#xD;
the Covid-19 group on day 2 and 7 while in the ICU&#xD;
the Covid-19 group after 3 and 12 months.</description>
    <arm_group_label>Cardiac Arrest</arm_group_label>
    <arm_group_label>Covid-19</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, plasma, and serum are stored at -80°C in the biobank BD-47 at IDEON, Lund,&#xD;
      Sweden.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All critically ill patients admitted to the participating ICUs in Region Skane (2015-2018),&#xD;
        and a healthy control group.&#xD;
&#xD;
        Starting in May 2020, critically ill Covid-19 patients admitted to an ICU in the Skane&#xD;
        Region are prospectively included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Critically ill patients admitted to the ICU&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  covid19-verified (covid19-cohort)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient or next of kin decline participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Friberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helena Levin, MSc</last_name>
    <phone>+46 46 176116</phone>
    <email>helena.levin@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans Friberg, MD, PhD</last_name>
    <phone>+46 708 144894</phone>
    <email>hans.a.friberg@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Annborn, MD, PhD</last_name>
      <email>martin.annborn@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kristianstad Central Hospital</name>
      <address>
        <city>Kristianstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Spångfors, RN, PhD</last_name>
      <email>martin.spangfors@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Lybeck, MD, PhD</last_name>
      <email>anna.lybeck@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Friberg, MD, PhD</last_name>
      <email>hans.friberg@skane.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Lengquist M, Lundberg OHM, Spångfors M, Annborn M, Levin H, Friberg H, Frigyesi A. Sepsis is underreported in Swedish intensive care units: A retrospective observational multicentre study. Acta Anaesthesiol Scand. 2020 Sep;64(8):1167-1176. doi: 10.1111/aas.13647. Epub 2020 Jun 18. Erratum in: Acta Anaesthesiol Scand. 2021 Jan;65(1):140.</citation>
    <PMID>32463121</PMID>
  </reference>
  <reference>
    <citation>Lundberg OHM, Lengquist M, Spångfors M, Annborn M, Bergmann D, Schulte J, Levin H, Melander O, Frigyesi A, Friberg H. Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness. Crit Care. 2020 Nov 4;24(1):636. doi: 10.1186/s13054-020-03351-1.</citation>
    <PMID>33148300</PMID>
  </reference>
  <reference>
    <citation>Thorgeirsdóttir B, Levin H, Spångfors M, Annborn M, Cronberg T, Nielsen N, Lybeck A, Friberg H, Frigyesi A. Plasma proenkephalin A 119-159 and dipeptidyl peptidase 3 on admission after cardiac arrest help predict long-term neurological outcome. Resuscitation. 2021 Jun;163:108-115. doi: 10.1016/j.resuscitation.2021.04.021. Epub 2021 Apr 27.</citation>
    <PMID>33930500</PMID>
  </reference>
  <reference>
    <citation>Johnsson J, Björnsson O, Andersson P, Jakobsson A, Cronberg T, Lilja G, Friberg H, Hassager C, Kjaergard J, Wise M, Nielsen N, Frigyesi A. Artificial neural networks improve early outcome prediction and risk classification in out-of-hospital cardiac arrest patients admitted to intensive care. Crit Care. 2020 Jul 30;24(1):474. doi: 10.1186/s13054-020-03103-1.</citation>
    <PMID>32731878</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skane University Hospital</investigator_affiliation>
    <investigator_full_name>Hans Friberg</investigator_full_name>
    <investigator_title>Professor, Consultant</investigator_title>
  </responsible_party>
  <keyword>Biobank</keyword>
  <keyword>Critical Illness</keyword>
  <keyword>Cardiac Arrest</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Influenza</keyword>
  <keyword>Covid-19</keyword>
  <keyword>Trauma</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Neurology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

